Promising Target for New Pancreatic Cancer Treatments Discovered by UNC Team

The lack of effective therapeutic options is a problem for pancreatic cancer patients as more than 38,000 people in the United States die of the disease each year

The lack of effective therapeutic options is a problem for pancreatic cancer patients as more than 38,000 people in the United States die of the disease each year, and new drugs and treatments are desperately needed.

For almost three decades, scientists and physicians have known that a gene called the KRAS oncogene is mutated in virtually all pancreatic cancers, making it an important target for scientists looking for a way to stop the growth of pancreatic cancer tumors. The problem is that the KRAS gene triggers cancer cell growth in numerous ways, through multiple cell signaling pathways, and scientists have had difficulty determining which one will be the most promising to block – an important first step in designing a drug for use in patients.

Pancreatic Cancer - All About the Disease, its Diagnosis and Management
Pancreatic cancer often involves its exocrine part. It grows aggressively, and often detected late. Treatment options include surgery, radiation and chemotherapy.

In a paper published today in the Journal of Biological Chemistry, a team from UNC Lineberger Comprehensive Cancer Center has narrowed the focus of this scientific quest to a protein called RGL2.

According to Channing Der, PhD, who led the research, "The pathway we talk about this paper is one we have investigating for more than five years. We think it is an attractive target for achieving what has, to date, been impossible: making a KRAS-blocking drug."

Der, who is a distinguished professor of pharmacology and UNC Lineberger member, says, "We are particularly optimistic about RGL2 because we know that this protein is a critical component of KRAS signaling to another class of proteins called Ral GTPases, which are essential for the growth of almost all pancreatic tumors."

Pancreatic Cancer Progression Very Slow
A surprising discovery reported by Johns Hopkins investigators about pancreatic cancer is that it develops and spreads very slowly, contrary to what scientists had believed earlier.

Working with Jen Jen Yeh, MD, assistant professor of surgery, Sharon Campbell, PhD, professor of biochemistry and biophysics, Der and his laboratory team were able to demonstrate that RGL2 is overexpressed – not only in pancreatic tumor cells grown in the laboratory but also in tissue taken from pancreatic cancer patients.

According to Der, "Many ideas work in the artificial environment of cell culture but not in real cancer patients. Our work with actual pancreatic tumor tissue makes us optimistic that our new understanding of this pathway can lead to a therapeutic impact for the cancer patient."

Study Says Stereotactic Radiotherapy Slows Pancreatic Cancer Progression for Inoperable Patients
DETROIT – For pancreatic cancer patients unable to undergo surgery – the only known cure for this form of cancer – a highly targeted cancer radiation therapy may help slow cancer progression

Source-Eurekalert